High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple...

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Tumor-specific mutations can create neoantigens, enhancing immune response in some cancers.
• Immune checkpoint inhibitors have shown limited efficacy in multiple myeloma (MM).
• Understanding the mutation and neoantigen landscape in MM is crucial for predicting treatment response.

Purpose of the Study:

• To investigate the relationship between mutation burden, neoantigen load, and therapeutic response in multiple myeloma patients.
• To identify if mutation and neoantigen profiles correlate with patient survival outcomes.

Main Methods:

• Analysis of interim data from the MMRF CoMMpass study (NCT01454297) including 664 MM patients.
• Quantification of somatic mutation burden and neoantigen load (predicted and expressed).
• Survival analysis, including progression-free survival (PFS), correlated with mutation and neoantigen levels.

Main Results:

• A strong positive linear correlation (R²=0.862) was observed between mutation and neoantigen burdens.
• Higher than average somatic missense mutation load and predicted expressed neoantigen load were associated with significantly shorter progression-free survival (PFS).
• These findings remained consistent across different disease stages and cytogenetic abnormalities.

Conclusions:

• Elevated mutation and neoantigen loads are significant negative prognostic factors in multiple myeloma.
• These factors negatively impact survival outcomes in MM patients receiving current standard care.
• Further research into targeted therapies based on the tumor's molecular profile is warranted.